ZT: COVID-19 vaccine efficacy summary

https://www.healthdata.org/covid/covid-19-vaccine-efficacy-summary

 注意最右邊兩個變種的數據，沒有一個疫苗達到世衛和FDA的標準（50%防感染)

 

上表未包括雙價疫苗。可以參考下麵的數據

https://www.bloomberg.com/news/articles/2022-11-22/new-bivalent-covid-boosters-provide-some-protection-in-cdc-study-but-not-much?leadSource=uverify%20wall

The bivalent boosters were just 43% effective at preventing mild illness compared to receiving no vaccine in adults 49 and under, according to a US Centers for Disease Control and Prevention study published Tuesday. In those aged 50 to 64 years, comparative protection against symptomatic Covid was 28%, while the booster was just 22% protective in adults 65 and older, the study showed. 

這個就是吃教授要引入中國給老年人打的疫苗。且不說價格，就那個22%保護率，誰能接受。

 

 

然而，疫苗公司堅持說雙價疫苗提高了抗體多少倍。但沒給出臨床有效性數據。

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted

• One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the companies’ original COVID-19 vaccine
• Neutralizing antibody titers against Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 increased 4.8- to 11.1-fold from pre-booster levels, following a 30-µg booster dose of the bivalent vaccine
•  

 

 

同期，有研究指出

More adverse reactions following bivalent COVID-19 mRNA booster vaccine

https://www.news-medical.net/news/20221113/More-adverse-reactions-following-bivalent-COVID-19-mRNA-booster-vaccine.aspx